Clinical trialNCT06899178RecruitingPhase 2Interventional

Atomoxetine in Melanocortin Obesity Syndrome

SponsorIcahn School of Medicine at Mount SinaiEnrollment20MCOSMelanocortin Obesity Syndrome

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase 2 randomized placebo-controlled crossover trial to determine the safety and efficacy of atomoxetine for treating obesity caused by loss-of-function variants in the melanocortin-4 receptor (MC4R), the most common cause of genetic obesity disorders. Atomoxetine was selected for this pilot trial because it has been shown to increase brain-derived neurotrophic factor (BDNF) within the central nervous system and in peripheral circulation. Targeting BDNF is a specific strategy for treating MC4R abnormalities because BDNF functions as a downstream mediator of MC4R signaling.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Ashley H Shoemaker, MD, MSCI
Vanderbilt University Medical Center
Principal Investigator
clinicaltrials.gov ↗
Joan C Han, MD
Mount Sinai Kravis Children's Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mount Sinai Hospital
New York, New York, United States
Joan Han
Recruiting
Nationwide Children'S Hospital
Columbus, Ohio, United States
Joan Han, MD
Not, yet, recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Ashley Shoemaker
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atomoxetine →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Sept 2026
Primary completion: 31 Mar 2028
Completion: 30 Jun 2028
Last update posted: 7 Aug 2026
Registered enrollment: 20
Registry id: NCT06899178

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.